Galera to Participate in the BofA Securities 2021 Virtual Healthcare Conference
May 05 2021 - 7:00AM
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage
biopharmaceutical company focused on developing and commercializing
a pipeline of novel, proprietary therapeutics that have the
potential to transform radiotherapy in cancer, today announced that
Mel Sorensen, M.D., President and Chief Executive Officer, will
present at a fireside chat at the BofA Securities 2021 Virtual
Healthcare Conference on Wednesday, May 12, 2021, at 8:45 a.m. ET.
A live webcast of the presentation will be
accessible from the Investors page of Galera’s website,
investors.galeratx.com. An archived version of the webcast will be
available in the News & Events section of the Investors page of
Galera’s website for 30 days following the event.
About Galera Therapeutics
Galera Therapeutics, Inc. is a clinical-stage
biopharmaceutical company focused on developing and commercializing
a pipeline of novel, proprietary therapeutics that have the
potential to transform radiotherapy in cancer. Galera’s lead
product candidate is avasopasem manganese (GC4419, also referred to
as avasopasem), a selective small molecule dismutase mimetic
initially being developed for the reduction of radiation-induced
severe oral mucositis (SOM). Avasopasem is being studied in the
Phase 3 ROMAN trial to assess its ability to reduce the incidence
and severity of SOM induced by radiotherapy in patients with
locally advanced head and neck cancer (HNC), its lead indication.
It is also being studied in the EUSOM Phase 2a multi-center trial
in Europe assessing the safety of avasopasem in patients with HNC
undergoing standard-of-care radiotherapy, the AESOP Phase 2a trial
to assess its ability to reduce the incidence of esophagitis
induced by radiotherapy in patients with lung cancer, and a Phase 2
trial in hospitalized patients who are critically ill with
COVID-19. A pilot Phase 1/2 trial of avasopasem in combination with
stereotactic body radiation therapy (SBRT) in patients with locally
advanced pancreatic cancer (LAPC) has completed enrollment and
reported results, with follow-up ongoing. The FDA granted Fast
Track and Breakthrough Therapy designations to avasopasem for the
reduction of SOM induced by radiotherapy. Galera’s second dismutase
mimetic product candidate, GC4711, is being developed specifically
to augment the anti-cancer efficacy of SBRT, and is currently being
studied in the GRECO-1 Phase 1/2 trial in combination with SBRT in
patients with non-small cell lung cancer. Galera also intends to
initiate the GRECO-2 Phase 2b trial of GC4711 in combination with
SBRT in patients with LAPC. Galera is headquartered in Malvern, PA.
For more information, please visit
www.galeratx.com.
Investor Contacts:Christopher
DegnanGalera Therapeutics, Inc.610-725-1500cdegnan@galeratx.com
William WindhamSolebury
Trout646-378-2946wwindham@soleburytrout.com
Media Contact:Zara
LockshinSolebury Trout646-378-2960zlockshin@soleburytrout.com
Galera Therapeutics (NASDAQ:GRTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Galera Therapeutics (NASDAQ:GRTX)
Historical Stock Chart
From Sep 2023 to Sep 2024